PART I A. Overview We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties and multi-target mechanisms of action. We advance these candidates into clinical-stage development, where we are conducting Phase 1 and Phase 2 studies fo...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001326732-26-000015 | EDGAR | 77K words |
| 2025-02-27 | 2024-12-31 | 0001326732-25-000029 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001326732-24-000006 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0001628280-23-005127 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001558370-22-001969 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001558370-21-001522 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001558370-20-001256 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001558370-19-001049 | EDGAR | — |
| 2018-02-28 | 2017-12-31 | 0001558370-18-001202 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001558370-17-001196 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001326732-25-000087 | EDGAR | 22K words |
| 2025-08-06 | 2025-06-30 | 0001326732-25-000075 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001326732-25-000053 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001326732-24-000060 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001326732-24-000043 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001326732-24-000029 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001326732-23-000042 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001326732-23-000026 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016494 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001558370-22-016660 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001558370-22-011923 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001558370-22-007444 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-09 | 0001326732-26-000023 | EDGAR | 1K words |
| 2026-03-04 | 0001326732-26-000021 | EDGAR | — |
| 2026-02-25 | 0001326732-26-000014 | EDGAR | — |
| 2026-01-08 | 0001326732-26-000002 | EDGAR | — |
| 2025-11-05 | 0001326732-25-000086 | EDGAR | — |
| 2025-10-24 | 0001326732-25-000082 | EDGAR | — |
| 2025-08-06 | 0001326732-25-000074 | EDGAR | — |
| 2025-07-31 | 0001326732-25-000063 | EDGAR | — |
| 2025-06-13 | 0001326732-25-000057 | EDGAR | — |
| 2025-05-07 | 0001326732-25-000052 | EDGAR | — |
211 total filings indexed. 179 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001326732 |
| Ticker | XNCR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.xencor.com |
| Listed | 2013-12-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report